CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 559 enrolled
Drug / intervention
placebo +3 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00266227
NCT00266227Phase 3Completed
CompareCT.gov

A Phase III, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Retreatment With Rituximab in Subjects With Rheumatoid Arthritis Receiving Background Methotrexate

Genentech, Inc.·interventional·Posted Dec 16, 2005·Updated Oct 25, 2013

In Brief

A Phase 3 clinical trial evaluating placebo, rituximab, and 2 other interventions for Rheumatoid Arthritis. Completed, enrolled 559 participants.

Detailed Summary

This is a Phase III, randomized, double-blind, placebo-controlled, multicenter study evaluating the efficacy of retreatment with rituximab in subjects with active rheumatoid arthritis (RA) who are receiving Methotrexate (MTX).

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsRheumatoid Arthritis
Countries--
Collaborators--

Timeline

Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedDec 16, 2005
Enrollment StartJan 1, 2006
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 20.5 years ago

Interventions

placebodrug

Intravenous repeating dose

rituximabdrug

Intravenous repeating dose

methotrexatedrug

Oral or parenteral repeating dose

folatedrug

Intravenous repeating dose